We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Host–Virus Genetic Interactions Drive Nasopharyngeal Cancer Risk

By LabMedica International staff writers
Posted on 17 Apr 2026

Epstein–Barr virus (EBV) infects more than 95% of adults worldwide, yet only a small fraction develops EBV‑associated cancers such as nasopharyngeal carcinoma. More...

Explaining this divergence requires understanding how human and viral factors jointly influence disease risk. However, studies have typically analyzed host or pathogen genomes in isolation. A new study shows that specific interactions between human and viral genomes shape nasopharyngeal cancer risk.

Researchers at Columbia University Mailman School of Public Health implemented a large-scale genome-to-genome analysis to interrogate host–virus genetic interactions implicated in cancer. The approach jointly assessed human genetic variation and EBV sequence diversity rather than evaluating each genome separately. This design was used to identify combinations of human leukocyte antigen (HLA) alleles and EBV variants associated with nasopharyngeal carcinoma.

The team analyzed human genome-wide association data alongside EBV whole‑genome sequencing using a stepwise analytical framework that integrates statistical genetics with causal inference methods. The pipeline accounted for population structure in both human and viral genomes, relatedness among samples, and multiple testing. This enabled a systematic search for interaction effects across both genomes that would be missed by single‑genome analyses.

A key interaction emerged between the HLA allele HLA‑A*11:01 and a single‑nucleotide variant (85841G) in the EBV gene EBNA3B. Individuals with susceptible HLA backgrounds who were infected with high‑risk EBV strains carrying 85841G showed substantially elevated risk of nasopharyngeal carcinoma. Functional experiments demonstrated that the viral mutation generates a peptide presented by HLA‑A*11:01, eliciting HLA‑A*11:01‑restricted CD8+ T‑cell responses that kill EBV‑transformed B cells harboring 85841G strains.

The findings are published in Nature on April 15, 2026 under the title “EBV strain interacts with host HLA to drive nasopharyngeal carcinoma risk”. Provided materials emphasize the growing role of statistical genomics and causal inference as multiple genomic systems are integrated to clarify complex disease mechanisms. The study framework highlights how combined host–pathogen genetics can refine understanding of cancer susceptibility.

“Most genetic studies examine the host genome or the pathogen genome separately,” said Zhonghua Liu, ScD, assistant professor of Biostatistics at Columbia Mailman School and co‑senior author. “By analyzing both genomes together using advanced statistical genetics methods and causal inference-inspired interaction frameworks, we can identify and quantify genetic interactions that would otherwise remain hidden.”

Related Links
Columbia University Mailman School of Public Health


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Immunofluorescence Analyzer
IFA System
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.